Regeneron in Express Scripts’ Sights for Price WarDrew Armstrong and Caroline Chen
After igniting a price war over hepatitis C medicine that has roiled the pharmaceutical industry, Express Scripts Holding Co. is looking to reap savings from expensive new treatments for cancer and high cholesterol.
To continue reading this article you must be a Bloomberg Professional Service Subscriber.
If you believe that you may have received this message in error please let us know.
- Ivanka Trump Faces Courtroom Showdown Over $785 Sandals
- Uber Losing Battle in London After Regulator Revokes License
- Mercedes Plots Tesla Attack With $1 Billion U.S. Electric Push
- How Electric Cars Can Create the Biggest Disruption Since the iPhone
- Trump Boosts North Korea Sanctions, Adding Economic Pressure